Nasdaq · CIK 0001661181
ORGO Organogenesis Holdings Inc.
Insider trading from SEC Form 4. Last filing Mar 11, 2026. Close $1.29 on Oct 9, 2026, +1% from the 52-week low and -80% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
15
with a Form 4 at this company
Price and insider trades, last year
ORGOOct 9, 2026 · close 1.29
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Organogenesis Holdings Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 46Moderate | Michael Joseph Driscoll director buy | $27k 10,000 shares | +5% | +4% from low-58% from high | |
| 41Moderate | Arthur S Leibowitz director buy | $13k 5,000 shares | +2% | +4% from low-58% from high | |
| 40Moderate | Glenn H Nussdorf director sell | $1.0M 200,000 shares | -7% | +94% from low-21% from high | |
| 40Moderate | Glenn H Nussdorf director, owner sell | $1.6M 300,000 shares | -10% | +103% from low-18% from high | |
| 56Moderate | Glenn H Nussdorf director, owner buy | $1.1M 358,495 shares | - | +18% from low-52% from high | |
| 24Weak | Glenn H Nussdorf director, owner sell | $81k 22,776 shares | -6% | +34% from low-45% from high | |
| 50Moderate | Lori Freedman Chief Admin. and Legal Officer buy | $725k 252,264 shares | +42% | +12% from low-54% from high | |
| 31Weak | Michael Joseph Driscoll director sell | $128k 25,000 shares | -13% | - | |
| 37Weak | Gary S. Gillheeney President and CEO sell | $206k 61,200 shares | -2% | - | |
| 49Moderate | Gary S. Gillheeney President and CEO sell | $940k 259,332 shares | -8% | - | |
| 22Weak | Gary S. Gillheeney President and CEO sell | $212k 59,468 shares | -2% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 17, 2025 | Driscoll Michael Joseph Director | 25,000 0.02% of outstanding | $127k | Mar 4, 2025 | none |
| Dec 6, 2024 | Gillheeney Gary S. Officer | 380,000 0.29% of outstanding | $1.4M | Dec 6, 2024 | none |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | Michael Joseph Driscoll director | POpen-market purchase Class A Common Stock | +10,000 | $2.67 | $27k | 225,707 | Mar 11, 2026 |
| Mar 9, 2026 | Arthur S Leibowitz director | POpen-market purchase Class A Common Stock | +5,000 | $2.68 | $13k | 291,014 | Mar 11, 2026 |
| Mar 1, 2026 | Robert Cavorsi Vice President, Strategy | FTax withholding Class A Common Stock | -700 | $3.21 | $2,247 | 275,524 | Mar 3, 2026 |
| Feb 18, 2026 | Patrick Bilbo Chief Operating Officer | AGrant or award Class A Common Stock | +49,102 | $0.00 | $0 | 1,144,687 | Mar 3, 2026 |
| Feb 18, 2026 | Gary S. Gillheeney President and CEO | AGrant or award Class A Common Stock | +188,856 | $0.00 | $0 | 4,323,398 | Mar 3, 2026 |
| Feb 18, 2026 | Brian Grow Chief Commercial Officer | AGrant or award Class A Common Stock | +48,818 | $0.00 | $0 | 911,611 | Mar 3, 2026 |
| Feb 18, 2026 | David Francisco Chief Financial Officer | AGrant or award Class A Common Stock | +44,040 | $0.00 | $0 | 745,999 | Mar 3, 2026 |
| Feb 18, 2026 | Lori Freedman Chief Admin. and Legal Officer | AGrant or award Class A Common Stock | +43,212 | $0.00 | $0 | 1,038,054 | Mar 3, 2026 |
| Feb 18, 2026 | Robert Cavorsi Vice President, Strategy | AGrant or award Class A Common Stock | +16,454 | $0.00 | $0 | 281,711 | Mar 3, 2026 |
| Feb 18, 2026 | Antonio S. Montecalvo Vice President, Health Policy | AGrant or award Class A Common Stock | +11,330 | $0.00 | $0 | 230,016 | Mar 3, 2026 |
| Feb 18, 2026 | Patrick Bilbo Chief Operating Officer | FTax withholding Class A Common Stock | -16,375 | $3.84 | $63k | 1,128,312 | Mar 3, 2026 |
| Feb 18, 2026 | David Francisco Chief Financial Officer | FTax withholding Class A Common Stock | -14,687 | $3.84 | $56k | 731,312 | Mar 3, 2026 |
| Feb 18, 2026 | Antonio S. Montecalvo Vice President, Health Policy | FTax withholding Class A Common Stock | -3,778 | $3.84 | $15k | 226,238 | Mar 3, 2026 |
| Feb 18, 2026 | Lori Freedman Chief Admin. and Legal Officer | FTax withholding Class A Common Stock | -14,411 | $3.84 | $55k | 1,023,643 | Mar 3, 2026 |
| Feb 18, 2026 | Brian Grow Chief Commercial Officer | FTax withholding Class A Common Stock | -11,887 | $3.84 | $46k | 899,724 | Mar 3, 2026 |
| Feb 18, 2026 | Gary S. Gillheeney President and CEO | FTax withholding Class A Common Stock | -91,311 | $3.84 | $351k | 4,232,087 | Mar 3, 2026 |
| Feb 18, 2026 | Robert Cavorsi Vice President, Strategy | FTax withholding Class A Common Stock | -5,487 | $3.84 | $21k | 276,224 | Mar 3, 2026 |
| Feb 18, 2026 | David Francisco Chief Financial Officer | AGrant or award Class A Common Stock | +195,312 | $0.00 | $0 | 701,959 | Feb 20, 2026 |
| Feb 18, 2026 | Antonio S. Montecalvo Vice President, Health Policy | AGrant or award Class A Common Stock | +40,625 | $0.00 | $0 | 218,686 | Feb 20, 2026 |
| Feb 18, 2026 | Michele Ilene Korfin director | AGrant or award Class A Common Stock | +48,828 | $0.00 | $0 | 239,073 | Feb 20, 2026 |
| Feb 18, 2026 | Garrett Lustig director | AGrant or award Class A Common Stock | +48,828 | $0.00 | $0 | 125,742 | Feb 20, 2026 |
| Feb 18, 2026 | Patrick Bilbo Chief Operating Officer | AGrant or award Class A Common Stock | +210,937 | $0.00 | $0 | 1,095,585 | Feb 20, 2026 |
| Feb 18, 2026 | Gilberto Quintero director | AGrant or award Class A Common Stock | +48,828 | $0.00 | $0 | 239,073 | Feb 20, 2026 |
| Feb 18, 2026 | Robert Cavorsi Vice President, Strategy | AGrant or award Class A Common Stock | +93,750 | $0.00 | $0 | 265,257 | Feb 20, 2026 |
| Feb 18, 2026 | Jon L Giacomin director | AGrant or award Class A Common Stock | +48,828 | $0.00 | $0 | 241,026 | Feb 20, 2026 |
| Feb 18, 2026 | Prathyusha Duraibabu director | AGrant or award Class A Common Stock | +48,828 | $0.00 | $0 | 247,047 | Feb 20, 2026 |
| Feb 18, 2026 | Gary S. Gillheeney President and CEO | AGrant or award Class A Common Stock | +890,625 | $0.00 | $0 | 4,134,542 | Feb 20, 2026 |
| Feb 18, 2026 | Michael Joseph Driscoll director | AGrant or award Class A Common Stock | +48,828 | $0.00 | $0 | 215,707 | Feb 20, 2026 |
| Feb 18, 2026 | Brian Grow Chief Commercial Officer | AGrant or award Class A Common Stock | +234,375 | $0.00 | $0 | 862,793 | Feb 20, 2026 |
| Feb 18, 2026 | Lori Freedman Chief Admin. and Legal Officer | AGrant or award Class A Common Stock | +203,125 | $0.00 | $0 | 994,842 | Feb 20, 2026 |
| Feb 18, 2026 | Arthur S Leibowitz director | AGrant or award Class A Common Stock | +48,828 | $0.00 | $0 | 286,014 | Feb 20, 2026 |
| Feb 18, 2026 | Gary S. Gillheeney President and CEO | AGrant or award Class A Common Stock | +186,968 | $0.00 | $0 | 4,321,510 | Feb 20, 2026 |
| Feb 18, 2026 | Antonio S. Montecalvo Vice President, Health Policy | AGrant or award Class A Common Stock | +11,218 | $0.00 | $0 | 229,904 | Feb 20, 2026 |
| Feb 18, 2026 | Lori Freedman Chief Admin. and Legal Officer | AGrant or award Class A Common Stock | +42,780 | $0.00 | $0 | 1,037,622 | Feb 20, 2026 |
| Feb 18, 2026 | Patrick Bilbo Chief Operating Officer | AGrant or award Class A Common Stock | +48,612 | $0.00 | $0 | 1,144,197 | Feb 20, 2026 |
| Feb 18, 2026 | Robert Cavorsi Vice President, Strategy | AGrant or award Class A Common Stock | +16,290 | $0.00 | $0 | 281,547 | Feb 20, 2026 |
| Feb 18, 2026 | Brian Grow Chief Commercial Officer | AGrant or award Class A Common Stock | +48,330 | $0.00 | $0 | 911,123 | Feb 20, 2026 |
| Feb 18, 2026 | David Francisco Chief Financial Officer | AGrant or award Class A Common Stock | +43,602 | $0.00 | $0 | 745,561 | Feb 20, 2026 |
| Feb 18, 2026 | David Francisco Chief Financial Officer | FTax withholding Class A Common Stock | -14,541 | $3.84 | $56k | 731,020 | Feb 20, 2026 |
| Feb 18, 2026 | Lori Freedman Chief Admin. and Legal Officer | FTax withholding Class A Common Stock | -14,267 | $3.84 | $55k | 1,023,355 | Feb 20, 2026 |
| Feb 18, 2026 | Robert Cavorsi Vice President, Strategy | FTax withholding Class A Common Stock | -5,432 | $3.84 | $21k | 276,115 | Feb 20, 2026 |
| Feb 18, 2026 | Patrick Bilbo Chief Operating Officer | FTax withholding Class A Common Stock | -16,212 | $3.84 | $62k | 1,127,985 | Feb 20, 2026 |
| Feb 18, 2026 | Gary S. Gillheeney President and CEO | FTax withholding Class A Common Stock | -90,398 | $3.84 | $347k | 4,231,112 | Feb 20, 2026 |
| Feb 18, 2026 | Antonio S. Montecalvo Vice President, Health Policy | FTax withholding Class A Common Stock | -3,741 | $3.84 | $14k | 226,163 | Feb 20, 2026 |
| Feb 18, 2026 | Brian Grow Chief Commercial Officer | FTax withholding Class A Common Stock | -11,768 | $3.84 | $45k | 899,355 | Feb 20, 2026 |
| Feb 18, 2026 | David Francisco Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +111,358 | $0.00 | $0 | 111,358 | Feb 20, 2026 |
| Feb 18, 2026 | Antonio S. Montecalvo Vice President, Health Policy | AGrant or award Stock Option (Right to Buy)derivative | +23,162 | $0.00 | $0 | 23,162 | Feb 20, 2026 |
| Feb 18, 2026 | Lori Freedman Chief Admin. and Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +115,812 | $0.00 | $0 | 115,812 | Feb 20, 2026 |
| Feb 18, 2026 | Robert Cavorsi Vice President, Strategy | AGrant or award Stock Option (Right to Buy)derivative | +53,452 | $0.00 | $0 | 53,452 | Feb 20, 2026 |
| Feb 18, 2026 | Gary S. Gillheeney President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +507,795 | $0.00 | $0 | 507,795 | Feb 20, 2026 |
| Feb 18, 2026 | Brian Grow Chief Commercial Officer | AGrant or award Stock Option (Right to Buy)derivative | +133,630 | $0.00 | $0 | 133,630 | Feb 20, 2026 |
| Feb 18, 2026 | Patrick Bilbo Chief Operating Officer | AGrant or award Stock Option (Right to Buy)derivative | +120,267 | $0.00 | $0 | 120,267 | Feb 20, 2026 |
| Feb 15, 2026 | Lori Freedman Chief Admin. and Legal Officer | FTax withholding Class A Common Stock | -4,043 | $3.73 | $15k | 842,416 | Feb 18, 2026 |
| Feb 15, 2026 | Gary S. Gillheeney President and CEO | FTax withholding Class A Common Stock | -24,340 | $3.73 | $91k | 3,490,983 | Feb 18, 2026 |
| Feb 15, 2026 | Brian Grow Chief Commercial Officer | FTax withholding Class A Common Stock | -3,346 | $3.73 | $12k | 669,031 | Feb 18, 2026 |
| Feb 15, 2026 | Antonio S. Montecalvo Vice President, Health Policy | FTax withholding Class A Common Stock | -1,389 | $3.73 | $5,181 | 195,291 | Feb 18, 2026 |
| Feb 15, 2026 | Patrick Bilbo Chief Operating Officer | FTax withholding Class A Common Stock | -5,114 | $3.73 | $19k | 943,948 | Feb 18, 2026 |
| Feb 15, 2026 | Robert Cavorsi Vice President, Strategy | FTax withholding Class A Common Stock | -6,667 | $3.73 | $25k | 182,498 | Feb 18, 2026 |
| Feb 15, 2026 | David Francisco Chief Financial Officer | FTax withholding Class A Common Stock | -3,898 | $3.73 | $15k | 555,197 | Feb 18, 2026 |
| Feb 15, 2026 | Lori Freedman Chief Admin. and Legal Officer | FTax withholding Class A Common Stock | -24,428 | $3.73 | $91k | 817,988 | Feb 18, 2026 |
| Feb 15, 2026 | Gary S. Gillheeney President and CEO | FTax withholding Class A Common Stock | -78,646 | $3.73 | $293k | 3,412,337 | Feb 18, 2026 |
| Feb 15, 2026 | Brian Grow Chief Commercial Officer | FTax withholding Class A Common Stock | -18,910 | $3.73 | $71k | 650,121 | Feb 18, 2026 |
| Feb 15, 2026 | Antonio S. Montecalvo Vice President, Health Policy | FTax withholding Class A Common Stock | -9,607 | $3.73 | $36k | 185,684 | Feb 18, 2026 |
| Feb 15, 2026 | Patrick Bilbo Chief Operating Officer | FTax withholding Class A Common Stock | -28,331 | $3.73 | $106k | 915,617 | Feb 18, 2026 |
| Feb 15, 2026 | Robert Cavorsi Vice President, Strategy | FTax withholding Class A Common Stock | -5,549 | $3.73 | $21k | 176,949 | Feb 18, 2026 |
| Feb 15, 2026 | David Francisco Chief Financial Officer | FTax withholding Class A Common Stock | -21,412 | $3.73 | $80k | 533,785 | Feb 18, 2026 |
| Feb 15, 2026 | Lori Freedman Chief Admin. and Legal Officer | FTax withholding Class A Common Stock | -12,761 | $3.73 | $48k | 805,227 | Feb 18, 2026 |
| Feb 15, 2026 | Gary S. Gillheeney President and CEO | FTax withholding Class A Common Stock | -82,815 | $3.73 | $309k | 3,329,522 | Feb 18, 2026 |
| Feb 15, 2026 | Brian Grow Chief Commercial Officer | FTax withholding Class A Common Stock | -10,559 | $3.73 | $39k | 639,562 | Feb 18, 2026 |
| Feb 15, 2026 | Antonio S. Montecalvo Vice President, Health Policy | FTax withholding Class A Common Stock | -4,100 | $3.73 | $15k | 181,584 | Feb 18, 2026 |
| Feb 15, 2026 | Patrick Bilbo Chief Operating Officer | FTax withholding Class A Common Stock | -15,617 | $3.73 | $58k | 900,000 | Feb 18, 2026 |
| Feb 15, 2026 | Robert Cavorsi Vice President, Strategy | FTax withholding Class A Common Stock | -5,442 | $3.73 | $20k | 171,507 | Feb 18, 2026 |
| Feb 15, 2026 | David Francisco Chief Financial Officer | FTax withholding Class A Common Stock | -13,369 | $3.73 | $50k | 520,416 | Feb 18, 2026 |
| Feb 15, 2026 | Lori Freedman Chief Admin. and Legal Officer | FTax withholding Class A Common Stock | -13,510 | $3.73 | $50k | 791,717 | Feb 18, 2026 |
| Feb 15, 2026 | Gary S. Gillheeney President and CEO | FTax withholding Class A Common Stock | -85,605 | $3.73 | $319k | 3,243,917 | Feb 18, 2026 |
| Feb 15, 2026 | Brian Grow Chief Commercial Officer | FTax withholding Class A Common Stock | -11,144 | $3.73 | $42k | 628,418 | Feb 18, 2026 |
| Feb 15, 2026 | Antonio S. Montecalvo Vice President, Health Policy | FTax withholding Class A Common Stock | -3,523 | $3.73 | $13k | 178,061 | Feb 18, 2026 |
| Feb 15, 2026 | Patrick Bilbo Chief Operating Officer | FTax withholding Class A Common Stock | -15,352 | $3.73 | $57k | 884,648 | Feb 18, 2026 |
| Feb 15, 2026 | David Francisco Chief Financial Officer | FTax withholding Class A Common Stock | -13,769 | $3.73 | $51k | 506,647 | Feb 18, 2026 |
| Dec 16, 2025 | Glenn H Nussdorf director | SOpen-market sale Class A Common Stock | -200,000 | $5.14 | $1.0M | 2,565,591 | Dec 18, 2025 |
| Nov 24, 2025 | Glenn H Nussdorf director, owner | SOpen-market sale Class A Common Stock | -100,000 | $5.34 | $534k | 2,965,591 | Nov 26, 2025 |
| Nov 25, 2025 | Glenn H Nussdorf director, owner | SOpen-market sale Class A Common Stock | -12,043 | $5.30 | $64k | 2,953,548 | Nov 26, 2025 |
| Nov 26, 2025 | Glenn H Nussdorf director, owner | SOpen-market sale Class A Common Stock | -187,957 | $5.29 | $994k | 2,765,591 | Nov 26, 2025 |
| May 14, 2025 | Glenn H Nussdorf director, owner | POpen-market purchase Class A Common Stockindirect: By Glenn Nussdorf 10 Year Follow On Trust Dated 11-1-1998 | +251,001 | $3.09 | $775k | 251,001 | Nov 3, 2025 |
| May 15, 2025 | Glenn H Nussdorf director, owner | POpen-market purchase Class A Common Stockindirect: By Glenn Nussdorf 10 Year Follow On Trust Dated 11-1-1998 | +107,494 | $2.99 | $321k | 358,495 | Nov 3, 2025 |
| Jun 9, 2025 | Glenn H Nussdorf director, owner | SOpen-market sale Class A Common Stockindirect: By Glenn Nussdorf 10 Year Follow On Trust Dated 11-1-1998 | -4,156 | $3.50 | $15k | 354,339 | Nov 3, 2025 |
| Jun 10, 2025 | Glenn H Nussdorf director, owner | SOpen-market sale Class A Common Stockindirect: By Glenn Nussdorf 10 Year Follow On Trust Dated 11-1-1998 | -18,620 | $3.56 | $66k | 335,719 | Nov 3, 2025 |
| Aug 11, 2025 | Brian Grow Chief Commercial Officer | MOption exercise Class A Common Stock | +4,060 | $2.47 | $10k | 674,550 | Aug 13, 2025 |
| Aug 11, 2025 | Brian Grow Chief Commercial Officer | FTax withholding Class A Common Stock | -2,173 | $4.62 | $10k | 672,377 | Aug 13, 2025 |
| Aug 11, 2025 | Brian Grow Chief Commercial Officer | MOption exercise Stock Option (Right to Buy)derivative | -4,060 | $0.00 | $0 | 0 | Aug 13, 2025 |
| Jul 16, 2025 | Robert Cavorsi Vice President, Strategy | FTax withholding Class A Common Stock | -360 | $4.47 | $1,607 | 189,165 | Jul 18, 2025 |
| Jun 4, 2025 | Lori Freedman Chief Admin. and Legal Officer | POpen-market purchase Class A Common Stock | +100,863 | $2.82 | $285k | 695,058 | Jun 6, 2025 |
| Jun 5, 2025 | Lori Freedman Chief Admin. and Legal Officer | POpen-market purchase Class A Common Stock | +142,379 | $2.91 | $414k | 837,437 | Jun 6, 2025 |
| Jun 6, 2025 | Lori Freedman Chief Admin. and Legal Officer | POpen-market purchase Class A Common Stock | +9,022 | $2.99 | $27k | 846,459 | Jun 6, 2025 |
| Mar 9, 2025 | Robert Cavorsi Vice President, Strategy | FTax withholding Class A Common Stock | -210 | $5.16 | $1,084 | 189,586 | Mar 12, 2025 |
| Mar 9, 2025 | Robert Cavorsi Vice President, Strategy | FTax withholding Class A Common Stock | -61 | $5.16 | $315 | 189,525 | Mar 12, 2025 |
| Mar 4, 2025 | Michael Joseph Driscoll director | SOpen-market sale Class A Common Stock | -25,000 | $5.10 | $128k | 166,879 | Mar 6, 2025 |
| Mar 1, 2025 | Robert Cavorsi Vice President, Strategy | FTax withholding Class A Common Stock | -667 | $6.21 | $4,142 | 189,796 | Mar 4, 2025 |
| Feb 19, 2025 | Robert Cavorsi Vice President, Strategy | AGrant or award Class A Common Stock | +61,705 | $0.00 | $0 | 190,463 | Feb 21, 2025 |
| Feb 19, 2025 | Patrick Bilbo Chief Operating Officer | AGrant or award Class A Common Stock | +184,136 | $0.00 | $0 | 949,062 | Feb 21, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Patrick BilboChief Operating Officer
- Robert CavorsiVice President, Strategy
- Michael Joseph Driscolldirector
- Prathyusha Duraibabucfo, officer, director
- David FranciscoChief Financial Officer
- Lori FreedmanChief Admin. and Legal Officer
- Jon L Giacomindirector
- Gary S. GillheeneyPresident and CEO
- Brian GrowChief Commercial Officer
- Michele Ilene Korfindirector
- Arthur S Leibowitzdirector
- Garrett Lustigdirector
- Antonio S. MontecalvoVice President, Health Policy
- Glenn H Nussdorfdirector, owner
- Gilberto Quinterodirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.